{"schema_version":"1.0","hypothesis_id":38993,"triple":{"drug":"baricitinib","drug_canonical":"baricitinib","mediator":"JAK2","mediator_canonical":"jak2","outcome":"poor prognosis","outcome_canonical":null},"domain":{"domain":"cross_domain","source":"rheumatoid_arthritis","target":"pancreatic_cancer"},"provenance_completeness":"partial_backfill","completeness_notes":"Backfilled retroactively from DB state on 2026-05-13. The pipeline_run this row references was created by the backfill script, not by the actual generation orchestrator. Source papers, claims, scoring, and embedding config are recovered; generation-time metadata (exact git commit at gen time, host, exact command) is not recoverable.","source_papers":[{"doi":"10.1093/mrcr/rxad012","pmid":"37249471","year":2023,"roles":["drug_mediator"],"title":"A case in which baricitinib was effective for both rheumatoid arthritis and essential thrombocythemia","journal":"Mod Rheumatol Case Rep","work_id":299243,"publication_date":"2023-05-18"},{"doi":"10.1186/s13063-023-07087-5","pmid":"36793118","year":2023,"roles":["drug_mediator"],"title":"A multi-center, open-label, randomized study to explore efficacy and safety of baricitinib in active primary Sjogren’s syndrome patients","journal":"Trials","work_id":296613,"publication_date":"2023-02-15"},{"doi":"10.1097/ftd.0000000000001128","pmid":"37752637","year":2023,"roles":["drug_mediator"],"title":"A Novel LC-MS/MS Method for Therapeutic Drug Monitoring of Baricitinib in Plasma of Pediatric Patients","journal":"Ther Drug Monit","work_id":293054,"publication_date":"2023-09-25"},{"doi":"10.3389/fimmu.2022.932240","pmid":"35958600","year":2022,"roles":["drug_mediator"],"title":"Baricitinib therapy response in rheumatoid arthritis patients associates to STAT1 phosphorylation in monocytes","journal":"Front Immunol","work_id":290926,"publication_date":"2022-07-25"},{"doi":"10.1080/09546634.2022.2161812","pmid":"36546346","year":2022,"roles":["drug_mediator"],"title":"Safety of baricitinib for the treatment of atopic dermatitis over a median of 1.6 years and up to 3.9 years of treatment: an updated integrated analysis of eight clinical trials","journal":"J Dermatolog Treat","work_id":287194,"publication_date":"2022-12-22"},{"doi":"10.7759/cureus.20024","pmid":"34873553","year":2021,"roles":["drug_mediator"],"title":"Are There Any Ethnic Differences in the Response to Baricitinib for the Treatment of Rheumatoid Arthritis?","journal":"Cureus","work_id":303696,"publication_date":"2021-11-29"},{"doi":"10.1177/1759720x211014019","pmid":"34025783","year":2021,"roles":["drug_mediator"],"title":"Baricitinib in the treatment of rheumatoid arthritis: clinical and ultrasound evaluation of a real-life single-centre experience","journal":"Ther Adv Musculoskelet Dis","work_id":292269,"publication_date":"2021-01-01"},{"doi":"10.55563/clinexprheumatol/lfg83z","pmid":"33337992","year":2021,"roles":["drug_mediator"],"title":"Effectiveness and safety of baricitinib in rheumatoid arthritis: a monocentric, longitudinal, real-life experience","journal":"Clin Exp Rheumatol","work_id":290716,"publication_date":"2021-05-21"},{"doi":"10.55563/clinexprheumatol/pudtpo","pmid":"33338001","year":2021,"roles":["drug_mediator"],"title":"Efficacy and safety of baricitinib in 446 patients with rheumatoid arthritis: a real-life multicentre study","journal":"Clin Exp Rheumatol","work_id":288918,"publication_date":"2021-07-08"},{"doi":"10.1186/s13063-021-05651-5","pmid":"34627340","year":2021,"roles":["drug_mediator"],"title":"Clinical effectiveness and safety of baricitinib for the treatment of juvenile idiopathic arthritis-associated uveitis or chronic anterior antinuclear antibody-positive uveitis: study protocol for an open-label, adalimumab active-controlled phase 3 clinical trial (JUVE-BRIGHT)","journal":"Trials","work_id":286936,"publication_date":"2021-10-09"},{"doi":"10.1021/acs.jmedchem.0c01952","pmid":"33570945","year":2021,"roles":["drug_mediator"],"title":"Structural Insights into JAK2 Inhibition by Ruxolitinib, Fedratinib, and Derivatives Thereof","journal":"J Med Chem","work_id":286221,"publication_date":"2021-02-11"},{"doi":"10.2147/ceor.s231558","pmid":"32346301","year":2020,"roles":["drug_mediator"],"title":"<p>Cost-Effectiveness of a JAK1/JAK2 Inhibitor vs a Biologic Disease-Modifying Antirheumatic Drug (bDMARD) in a Treat-to-Target Strategy for Rheumatoid Arthritis</p>","journal":"Clinicoecon Outcomes Res","work_id":295132,"publication_date":"2020-04-01"},{"doi":"10.1136/annrheumdis-2019-216852","pmid":"32788396","year":2020,"roles":["drug_mediator"],"title":"Infections in baricitinib clinical trials for patients with active rheumatoid arthritis","journal":"Ann Rheum Dis","work_id":286357,"publication_date":"2020-08-11"},{"doi":"10.1155/2020/7656031","pmid":"33029256","year":2020,"roles":["mediator_outcome"],"title":"High JAK2 Protein Expression Predicts a Poor Prognosis in Patients with Resectable Pancreatic Ductal Adenocarcinoma","journal":"Dis Markers","work_id":174775,"publication_date":"2020-09-22"},{"doi":null,"pmid":"30767864","year":2019,"roles":["drug_mediator"],"title":"The effect of JAK1/JAK2 inhibition in rheumatoid arthritis: efficacy and safety of baricitinib.","journal":"Clin Exp Rheumatol","work_id":286853,"publication_date":"2019-07-29"},{"doi":"10.1186/s13075-019-1883-1","pmid":"30999933","year":2019,"roles":["drug_mediator"],"title":"Evaluation of pneumococcal and tetanus vaccine responses in patients with rheumatoid arthritis receiving baricitinib: results from a long-term extension trial substudy","journal":"Arthritis Res Ther","work_id":286764,"publication_date":"2019-04-18"},{"doi":"10.3899/jrheum.171361","pmid":"30219772","year":2018,"roles":["drug_mediator"],"title":"Safety Profile of Baricitinib in Patients with Active Rheumatoid Arthritis with over 2 Years Median Time in Treatment","journal":"J Rheumatol","work_id":285971,"publication_date":"2018-09-15"}],"source_paper_count":17,"extracted_claims":[{"side":"drug_mediator","object":"JAK2","context":"general","subject":"baricitinib","work_id":285971,"claim_id":206149,"polarity":"positive","predicate":"inhibits","confidence":0.95,"extraction_run_id":28},{"side":"drug_mediator","object":"JAK2","context":"in rheumatoid arthritis","subject":"baricitinib","work_id":286221,"claim_id":206733,"polarity":"positive","predicate":"inhibits","confidence":0.7,"extraction_run_id":29},{"side":"drug_mediator","object":"JAK2","context":"rheumatoid arthritis treatment","subject":"baricitinib","work_id":286357,"claim_id":207112,"polarity":"positive","predicate":"inhibits","confidence":0.95,"extraction_run_id":29},{"side":"drug_mediator","object":"JAK2","context":"in patients with rheumatoid arthritis","subject":"baricitinib","work_id":286764,"claim_id":208079,"polarity":"positive","predicate":"inhibits","confidence":0.95,"extraction_run_id":29},{"side":"drug_mediator","object":"JAK2","context":"in rheumatoid arthritis","subject":"baricitinib","work_id":286853,"claim_id":208289,"polarity":"positive","predicate":"inhibits","confidence":0.95,"extraction_run_id":29},{"side":"drug_mediator","object":"JAK2","context":"general","subject":"baricitinib","work_id":286936,"claim_id":208528,"polarity":"positive","predicate":"inhibits","confidence":1.0,"extraction_run_id":29},{"side":"drug_mediator","object":"JAK2","context":"general","subject":"baricitinib","work_id":287194,"claim_id":209137,"polarity":"positive","predicate":"inhibits","confidence":0.95,"extraction_run_id":29},{"side":"drug_mediator","object":"JAK2","context":"in rheumatoid arthritis patients","subject":"baricitinib","work_id":288918,"claim_id":215633,"polarity":"positive","predicate":"inhibits","confidence":0.9,"extraction_run_id":29},{"side":"drug_mediator","object":"JAK2","context":"in rheumatoid arthritis","subject":"baricitinib","work_id":290716,"claim_id":223048,"polarity":"positive","predicate":"inhibits","confidence":0.95,"extraction_run_id":29},{"side":"drug_mediator","object":"JAK2","context":"general","subject":"baricitinib","work_id":290926,"claim_id":224057,"polarity":"positive","predicate":"inhibits","confidence":0.9,"extraction_run_id":29},{"side":"drug_mediator","object":"JAK2","context":"rheumatoid arthritis","subject":"Baricitinib","work_id":292269,"claim_id":229665,"polarity":"positive","predicate":"inhibits","confidence":0.9,"extraction_run_id":29},{"side":"drug_mediator","object":"JAK2","context":"as a selective and reversible JAK1/JAK2 inhibitor","subject":"baricitinib","work_id":293054,"claim_id":232685,"polarity":"positive","predicate":"inhibits","confidence":0.8,"extraction_run_id":29},{"side":"drug_mediator","object":"JAK2","context":"","subject":"baricitinib","work_id":295132,"claim_id":240400,"polarity":"positive","predicate":"inhibits","confidence":0.95,"extraction_run_id":29},{"side":"drug_mediator","object":"JAK2","context":"in active primary Sjogren's syndrome patients","subject":"Baricitinib","work_id":296613,"claim_id":244381,"polarity":"positive","predicate":"inhibits","confidence":0.9,"extraction_run_id":29},{"side":"drug_mediator","object":"JAK2","context":"in vitro (implied by drug class)","subject":"baricitinib","work_id":299243,"claim_id":252464,"polarity":"positive","predicate":"inhibits","confidence":0.95,"extraction_run_id":29},{"side":"drug_mediator","object":"JAK2","context":"treatment of rheumatoid arthritis","subject":"baricitinib","work_id":303696,"claim_id":264839,"polarity":"positive","predicate":"inhibits","confidence":0.95,"extraction_run_id":29},{"side":"mediator_outcome","object":"poor prognosis","context":"in patients with resectable pancreatic ductal adenocarcinoma","subject":"JAK2","work_id":174775,"claim_id":128463,"polarity":"positive","predicate":"predicts","confidence":0.95,"extraction_run_id":23}],"extracted_claim_count":17,"extraction":{"model":"deepseek-v4-flash","model_source":"configured","prompt_version":"v1_2026_05_07","run_ids":[23,28,29]},"bridge":{"a_to_b_predicate":"inhibits","b_to_c_predicate":"predicts","a_to_b_evidence_count":16,"b_to_c_evidence_count":1,"edge_support_log_ab":2.833213344056216,"edge_support_log_bc":0.6931471805599453,"novelty_factor":1.0,"direct_a_to_c_count":0},"embedding":{"model":"bge-m3","dim":1024,"max_length":8192,"similarity_scores":{}},"scoring":{"method":"swanson_abc_log_evidence_with_novelty_penalty","formula":"score = min((log(ab+1) + log(bc+1)) * novelty / 10, 1.0); novelty = 1.0 if direct==0 else 0.7 / (direct+1)","score_raw":0.35263605246161617,"score":0.35263605246161617,"quality_tier":"high","quality_reason":null},"pipeline_run":{"id":4,"run_uuid":"eb8b7730-d92e-4cd5-95dd-95f6c5d62cc2","command":"scripts/backfill_provenance_v2.py:v2_2026_05_12","status":"completed","git_commit":"9996ffaa56e9b7cd5f677bd8203624c2c18aa000","host":"MacBook-Pro-Daniel96.local","started_at":"2026-05-12T21:35:53.363326+00:00","ended_at":"2026-05-12T21:43:41.903387+00:00","notes":"Retroactive provenance backfill on 2026-05-13 for snapshot v2_2026_05_12. Synthetic pipeline_runs row — original generation run records are lost (pre-date provenance schema). All recoverable fields populated from current DB state (claims, works, repurposing_hypotheses); pipeline_run record is synthetic, hence completeness='partial_backfill'.\nBackfilled 1,618 provenance rows. Source papers: avg=3.73, zero=0. Claims matched: avg=4.09, zero=0.\nRefreshed 1,618 provenance rows. Source papers: avg=3.73, zero=0. Claims matched: avg=4.09, zero=0.\nRefreshed 1,618 provenance rows. Source papers: avg=3.73, zero=0. Claims matched: avg=4.09, zero=0.","domains":["als","alzheimer","depression","epilepsy","glioblastoma","inflammatory_bowel_disease","multiple_sclerosis","pancreatic_cancer","rheumatoid_arthritis","type_2_diabetes"]},"generated_at":"2026-05-12T21:43:40.945575+00:00"}